Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous PRAME-targeting TCR-engineered T cells IMA203

A preparation of autologous T lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous PRAME-targeting TCR-engineered T cells IMA203 specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ACTengine IMA203
autologous T-cell receptor-engineered T cells IMA203
IMA203 autologous T lymphocytes
IMA203 T cells
Code name:IMA 2013
IMA 203
IMA-203
IMA203
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search